STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas

被引:165
作者
Chan, Szeman Ruby [1 ]
Vermi, William [2 ]
Luo, Jingqin [3 ]
Lucini, Laura [2 ]
Rickert, Charles [1 ]
Fowler, Amy M. [4 ]
Lonardi, Silvia [2 ]
Arthur, Cora [1 ]
Young, Larry J. T. [5 ]
Levy, David E. [6 ]
Welch, Michael J. [4 ]
Cardiff, Robert D. [5 ]
Schreiber, Robert D. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA
[2] Univ Brescia, Dept Pathol, Spedali Civilli Brescia, I-25123 Brescia, Italy
[3] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[4] Edward Mallinckrodt Inst Radiol, Div Radiol Sci, St Louis, MO 63110 USA
[5] Univ Calif Davis, Dept Pathol & Lab Med, Ctr Comparat Med, Davis, CA 95616 USA
[6] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
关键词
IFN-GAMMA; ENDOCRINE THERAPY; TARGETED DISRUPTION; STAT1; TUMOR; GENE; EXPRESSION; CELLS; MODEL; GLAND;
D O I
10.1186/bcr3100
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Introduction: Although breast cancers expressing estrogen receptor-alpha (ER alpha) and progesterone receptors (PR) are the most common form of mammary malignancy in humans, it has been difficult to develop a suitable mouse model showing similar steroid hormone responsiveness. STAT transcription factors play critical roles in mammary gland tumorigenesis, but the precise role of STAT1 remains unclear. Herein, we show that a subset of human breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ER alpha+/PR+ mammary tumors. Methods: We used a combination of approaches, including histological examination, gene targeted mice, gene expression analysis, tumor transplantaion, and immunophenotyping, to pursue this study. Results: Forty-five percent (37/83) of human ER alpha+ and 22% (17/78) of ER alpha- breast cancers display undetectable or low levels of STAT1 expression in neoplastic cells. In contrast, STAT1 expression is elevated in epithelial cells of normal breast tissues adjacent to the malignant lesions, suggesting that STAT1 is selectively downregulated in the tumor cells during tumor progression. Interestingly, the expression levels of STAT1 in the tumor-infiltrating stromal cells remain elevated, indicating that single-cell resolution analysis of STAT1 level in primary breast cancer biopsies is necessary for accurate assessment. Female mice lacking functional STAT1 spontaneously develop mammary adenocarcinomas that comprise > 90% ER alpha+/PR+ tumor cells, and depend on estrogen for tumor engraftment and progression. Phenotypic marker analyses demonstrate that STAT1(-/-)mammary tumors arise from luminal epithelial cells, but not myoepithelial cells. In addition, the molecular signature of the STAT1(-/-) mammary tumors overlaps closely to that of human luminal breast cancers. Finally, introduction of wildtype STAT1, but not a STAT1(-/-) mutant lacking the critical Tyr701 residue, into STAT1(-/-)mammary tumor cells results in apoptosis, demonstrating that the tumor suppressor function of STAT1 is cell-autonomous and requires its transcriptional activity. Conclusions: Our findings demonstrate that STAT1 suppresses mammary tumor formation and its expression is frequently lost during breast cancer progression. Spontaneous mammary tumors that develop in STAT1(-/-)mice closely recapitulate the progression, ovarian hormone responsiveness, and molecular characteristics of human luminal breast cancer, the most common subtype of human breast neoplasms, and thus represent a valuable platform for testing novel treatments and detection modalities.
引用
收藏
页数:21
相关论文
共 60 条
[1]
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]
HORMONE-DEPENDENT MAMMARY-TUMORS IN STRAIN GR-A MICE .3. EFFECTIVENESS OF SUPPLEMENTARY HORMONE TREATMENTS IN INDUCING TUMOROUS PHASE GROWTH [J].
AIDELLS, BD ;
DANIEL, CW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1976, 57 (03) :527-537
[3]
Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chatterjee, N ;
Ershler, WB ;
Brawley, OW .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36
[4]
Steroid hormone receptor status of mouse mammary stem cells [J].
Asselin-Labat, Marie-Liesse ;
Shackleton, Mark ;
Stingl, John ;
Vaillant, Francois ;
Forrest, Natasha C. ;
Eaves, Connie J. ;
Visvader, Jane E. ;
Lindeman, Geoffrey J. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (14) :1011-1014
[5]
The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].
Bach, EA ;
Aguet, M ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&
[6]
Prognostic and predictive factors in breast cancer [J].
Bundred, NJ .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :137-142
[7]
Cancer Biomedical Informatics Grid National Cancer Institute, DIST WEIGHT DISCR
[8]
Precancer in mice: Animal models used to understand, prevent, and treat human precancers [J].
Cardiff, Robert D. ;
Anver, Miriam R. ;
Boivin, Gregory P. ;
Bosenberg, Marcus W. ;
Maronpot, Robert R. ;
Molinolo, Alfredo A. ;
Nikitin, Alexander Yu ;
Rehg, Jerold E. ;
Thomas, George V. ;
Russell, Robert G. ;
Ward, Jerrold M. .
TOXICOLOGIC PATHOLOGY, 2006, 34 (06) :699-707
[9]
A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays [J].
Charpin, Colette ;
Secq, Veronique ;
Giusiano, Sophie ;
Carpentier, Severine ;
Andrac, Lucile ;
Lavaut, Marie-Noelle ;
Allasia, Claude ;
Bonnier, Pascal ;
Garcia, Stephane .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (09) :2124-2134
[10]
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool [J].
Chia, Y. H. ;
Ellis, M. J. ;
Ma, C. X. .
BRITISH JOURNAL OF CANCER, 2010, 103 (06) :759-764